1. Effect of Jardiance on glucose uptake into astrocytomas
- Author
-
Ghezzi, Chiara, Ellingson, Benjamin M, Lai, Albert, Liu, Jie, Barrio, Jorge R, and Wright, Ernest M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Brain Disorders ,Diabetes ,Clinical Research ,Brain Cancer ,Cancer ,Rare Diseases ,Biomedical Imaging ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,5.1 Pharmaceuticals ,Humans ,Astrocytoma ,Brain Neoplasms ,Glucose ,Sodium-Glucose Transporter 2 Inhibitors ,Male ,Sodium-Glucose Transporter 2 ,Positron-Emission Tomography ,Glucosides ,Female ,Middle Aged ,Fluorodeoxyglucose F18 ,Aged ,Glioblastoma ,Me4FDG ,PET ,SGLT2 ,SGLT2i ,Neurosciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
PurposeSGLT2, the sodium glucose cotransporter two, is expressed in human pancreatic, prostate and brain tumors, and in a mouse cancer model SGLT2 inhibitors reduce tumor glucose uptake and growth. In this study we have measured the effect of a specific SGLT2 inhibitor, Jardiance® (Empagliflozin), on glucose uptake into astrocytomas in patients.MethodsWe have used a specific SGLT glucose tracer, α-methyl-4-[18F]fluoro-4-deoxy-α-D-glucopyranoside (Me4FDG), and Positron Emission Tomography (PET) to measure glucose uptake. Four of five patients enrolled had WHO grade IV glioblastomas, and one had a low grade WHO Grade II astrocytoma. Two dynamic brain PET scans were conducted on each patient, one before and one after treatment with a single oral dose of Jardiance, a specific SGLT2 inhibitor. As a control, we also determined the effect of oral Jardiance on renal SGLT2 activity.ResultsIn all five patients an oral dose (25 or 100 mg) of Jardiance reduced Me4FDG tumor accumulation, highly significant inhibition in four, and inhibited SGLT2 activity in the kidney.ConclusionsThese initial experiments show that SGLT2 is a functional glucose transporter in astocytomas, and Jardiance inhibited glucose uptake, a drug approved by the FDA to treat type 2 diabetes mellitus (T2DM), heart failure, and renal failure. We suggest that clinical trials be initiated to determine whether Jardiance reduces astrocytoma growth in patients.
- Published
- 2024